The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes

Bone

Volumn 94, Issue , 2017, Pages 141-151

  Thrailkill, Kathryn M ^a   Nyman, Jeffry S ^b   Bunn, R Clay ^a   Uppuganti, Sasidhar ^b   Thompson, Katherine L ^c   Lumpkin, Charles K ^d   Kalaitzoglou, Evangelia ^a   Fowlkes, John L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bone microarchitecture; Canagliflozin; Cortical bone; Dapagliflozin; Glycosuria; Hypercalciuria; Trabecular bone

Indexed keywords

CANAGLIFLOZIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN A1C; INSULIN; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MICROARCHITECTURE; BONE STRENGTH; BONE TURNOVER; CALCIUM EXCRETION; CALCIUM URINE LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICAL BONE; DIABETIC BONE DISEASE; DRUG EFFICACY; FEMUR; FEMUR MIDSHAFT; FRACTURE RESISTANCE; GENERAL ASPECTS OF DISEASE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LUMBAR VERTEBRA; MALE; METABOLIC REGULATION; MONOTHERAPY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; PHENOTYPE; TRABECULAR BONE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BONE; COMPLICATION; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLIC BONE DISEASE; METABOLISM; PATHOLOGY; STATISTICAL MODEL;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; BONE AND BONES; BONE DISEASES, METABOLIC; BONE RESORPTION; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; INSULIN; LINEAR MODELS; MALE; MICE, INBRED DBA; PHENOTYPE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84994644951     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.10.026     Document Type: Article

References (46)

1. [1] Lecka-Czernik, B., Fowlkes, J., (eds.) Diabetic Bone Disease, first ed., 2016, Springer International Publishing (230 pp).
2. [2] Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W., List, J.F., Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:10 (2010), 2217–2224 http://dx.doi.org/10.2337/dc10-0612 (PubMed PMID: 20566676; PubMed Central PMCID: PMC2945163).
3. [3] Kaku, K., Watada, H., Iwamoto, Y., Utsunomiya, K., Terauchi, Y., Tobe, K., Tanizawa, Y., Araki, E., Ueda, M., Suganami, H., Watanabe, D., Tofogliflozin 003 Study G. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc. Diabetol., 13, 2014, 65, 10.1186/1475-2840-13-65 (PubMed PMID: 24678906; PubMed Central PMCID: PMC4021346).
4. [4] Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., Dapagliflozin 006 study G. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann. Intern. Med. 156:6 (2012), 405–415, 10.7326/0003-4819-156-6-201203200-00003 (PubMed PMID: 22431673).
5. [5] Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C., Investigators, E.-R.M.T., Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:7 (2014), 1815–1823, 10.2337/dc13-3055 (PubMed PMID: 24929430.
6. [6] DeFronzo, R.A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., Broedl, U.C., Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38:3 (2015), 384–393, 10.2337/dc14-2364 (PubMed PMID: 25583754.
7. [7] Guthrie, R.M., Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgrad. Med. 127:5 (2015), 463–479, 10.1080/00325481.2015.1044756 (PubMed PMID: 25956345).
8. [8] Kovacs, C.S., Seshiah, V., Merker, L., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H.J., Broedl, U.C., investigators E-REP, Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clin. Ther., 2015, 10.1016/j.clinthera.2015.05.511 (PubMed PMID: 26138864.
9. [9] Mathieu, C., Ranetti, A.E., Li, D., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Hansen, L., Iqbal, N., A randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to Saxagliptin plus metformin in type 2 diabetes. Diabetes Care, 2015, 10.2337/dc15-0779 (PubMed PMID: 26246458).
10. [10] Perkins, B.A., Cherney, D.Z., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N.M., Kaspers, S., Woerle, H.J., Broedl, U.C., Johansen, O.E., Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:5 (2014), 1480–1483, 10.2337/dc13-2338 (PubMed PMID: 24595630).
11. [11] Bell, D.S., Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep. Endocrinol., 2015, 2015, 676191, 10.1155/2015/676191 (PubMed PMID: 25785209; PubMed Central PMCID: PMC4345240).
12. [12] Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:9 (2015), 1687–1693, 10.2337/dc15-0843 (PubMed PMID: 26078479; PubMed Central PMCID: PMC4542270).
13. [13] Sands, A.T., Zambrowicz, B.P., Rosenstock, J., Lapuerta, P., Bode, B.W., Garg, S.K., Buse, J.B., Banks, P., Heptulla, R., Rendell, M., Cefalu, W.T., Strumph, P., Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care, 2015, 10.2337/dc14-2806 (PubMed PMID: 26049551).
14. [14] Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., Pfister, M., Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85:5 (2009), 520–526, 10.1038/clpt.2008.251 (PubMed PMID: 19129748).
15. [15] Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., Rothenberg, P., Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metab. 13:7 (2011), 669–672, 10.1111/j.1463-1326.2011.01406.x (PubMed PMID: 21457428).
16. [16] Nauck, M.A., Del Prato, S., Duran-Garcia, S., Rohwedder, K., Langkilde, A.M., Sugg, J., Parikh, S.J., Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes. Metab. 16:11 (2014), 1111–1120, 10.1111/dom.12327 (PubMed PMID: 24919526).
17. [17] Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A., Renal Sodium-Glucose Cotransporter Inhibition in the Management of Type 2 Diabetes Mellitus. Am. J. Physiol. Ren. Physiol., 2015, 10.1152/ajprenal.00267.2015 ajprenal 00267 2015 (PubMed PMID: 26354881).
18. [18] Taylor, S.I., Blau, J.E., Rother, K.I., Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 3:1 (2015), 8–10, 10.1016/S2213-8587(14)70227-X (PubMed PMID: 25523498).
19. [19] Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85:4 (2014), 962–971, 10.1038/ki.2013.356 (PubMed PMID: 24067431; PubMed Central PMCID: PMC3973038).
20. [20] Gregorio, F., Cristallini, S., Santeusanio, F., Filipponi, P., Fumelli, P., Osteopenia associated with non-insulin-dependent diabetes mellitus: What are the causes?. Diabetes Res. Clin. Pract. 23:1 (1994), 43–54 (PubMed PMID: 8013262.
21. [21] Thrailkill, K.M., Clay Bunn, R., Nyman, J.S., Rettiganti, M.R., Cockrell, G.E., Wahl, E.C., Uppuganti, S., Lumpkin, C.K. Jr., Fowlkes, J.L., SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Bone, 2015, 10.1016/j.bone.2015.07.025 (PubMed PMID: 26211996).
22. [22] Fowlkes, J.L., Nyman, J.S., Bunn, R.C., Cockrell, G.E., Wahl, E.C., Rettiganti, M.R., Lumpkin, C.K. Jr., Thrailkill, K.M., Effects of long-term doxycycline on bone quality and strength in diabetic male DBA/2J mice. Bone Rep. 1 (2015), 16–19, 10.1016/j.bonr.2014.10.001 (PubMed PMID: 25685827; PubMed Central PMCID: PMC4324548).
23. [23] Uppuganti, S., Granke, M., Makowski, A.J., Does, M.D., Nyman, J.S., Age-related changes in the fracture resistance of male Fischer F344 rat bone. Bone 83 (2016), 220–232, 10.1016/j.bone.2015.11.009 (PubMed PMID: 26610688; PubMed Central PMCID: PMC4724327).
24. [24] Zhang, M., Xuan, S., Bouxsein, M.L., von Stechow, D., Akeno, N., Faugere, M.C., Malluche, H., Zhao, G., Rosen, C.J., Efstratiadis, A., Clemens, T.L., Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277:46 (2002), 44005–44012, 10.1074/jbc.M208265200 (PubMed PMID: 12215457).
25. [25] Quarles, L.D., Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp. Cell Res. 318:9 (2012), 1040–1048, 10.1016/j.yexcr.2012.02.027 (PubMed PMID: 22421513; PubMed Central PMCID: PMC3336874).
26. [26] Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57:1 (1995), 289–300.
27. [27] Thrailkill, K.M., Liu, L., Wahl, E.C., Bunn, R.C., Perrien, D.S., Cockrell, G.E., Skinner, R.A., Hogue, W.R., Carver, A.A., Fowlkes, J.L., Aronson, J., Lumpkin, C.K. Jr., Bone formation is impaired in a model of type 1 diabetes. Diabetes 54:10 (2005), 2875–2881 (PubMed PMID: 16186388).
28. [28] Nyman, J.S., Even, J.L., Jo, C.H., Herbert, E.G., Murry, M.R., Cockrell, G.E., Wahl, E.C., Bunn, R.C., Lumpkin, C.K. Jr., Fowlkes, J.L., Thrailkill, K.M., Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone 48:4 (2011), 733–740, 10.1016/j.bone.2010.12.016 (PubMed PMID: 21185416; PubMed Central PMCID: PMC3062641).
29. [29] Acute effects of canagliflozin on bone metabolism: Preliminary results from a randomized, placebo-controlled trial. JE, B., Bauman, V., Piaggi, P., MT, C., SI, T., KI, R., (eds.) 76th Scientific Sessions of the ADA, 2016, American Diabetes Association, New Orleans, LA.
30. [30] Alba, M., Xie, J., Fung, A., Desai, M., The Effects of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, on Mineral Metabolism and Bone in Patients With Type 2 Diabetes Mellitus. Curr. Med. Res. Opin., 2016, 1–34, 10.1080/03007995.2016.1174841 (PubMed PMID: 27046479).
31. [31] List, J.F., Woo, V., Morales, E., Tang, W., Fiedorek, F.T., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:4 (2009), 650–657, 10.2337/dc08-1863 (PubMed PMID: 19114612; PubMed Central PMCID: PMC2660449).
32. [32] Bilezikian, J.P., Watts, N.B., Usiskin, K., Polidori, D., Fung, A., Sullivan, D., Rosenthal, N., Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101:1 (2016), 44–51, 10.1210/jc.2015-1860 (PubMed PMID: 26580234; PubMed Central PMCID: PMC4701848).
33. [33] Ljunggren, O., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A.M., Sjostrom, C.D., Sugg, J., Parikh, S., Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes. Metab. 14:11 (2012), 990–999, 10.1111/j.1463-1326.2012.01630.x (PubMed PMID: 22651373).
34. [34] Kohler, S., Salsali, A., Hantel, S., Kaspers, S., Woerle, H.J., Kim, G., Broedl, U.C., Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin. Ther., 2016, 10.1016/j.clinthera.2016.03.031 (PubMed PMID: 27085585).
35. [35] Wei, J., Shimazu, J., Makinistoglu, M.P., Maurizi, A., Kajimura, D., Zong, H., Takarada, T., Lezaki, T., Pessin, J.E., Hinoi, E., Karsenty, G., Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation. Cell 161:7 (2015), 1576–1591, 10.1016/j.cell.2015.05.029 (PubMed PMID: 26091038; PubMed Central PMCID: PMC4475280).
36. [36] Thomas, D.M., Maher, F., Rogers, S.D., Best, J.D., Expression and regulation by insulin of GLUT 3 in UMR 106-01, a clonal rat osteosarcoma cell line. Biochem. Biophys. Res. Commun. 218:3 (1996), 789–793, 10.1006/bbrc.1996.0140 (PubMed PMID: 8579592).
37. [37] Zoidis, E., Ghirlanda-Keller, C., Schmid, C., Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I. Mol. Cell. Biochem. 348:1–2 (2011), 33–42, 10.1007/s11010-010-0634-z PubMed PMID: 21076856).
38. [38] Cheng, S.T., Chen, L., Li, S.Y., Mayoux, E., Leung, P.S., The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes. PLoS One, 11(1), 2016, e0147391, 10.1371/journal.pone.0147391 (PubMed PMID: 26807719; PubMed Central PMCID: PMC4726656).
39. [39] Okauchi, S., Shimoda, M., Obata, A., Kimura, T., Hirukawa, H., Kohara, K., Mune, T., Kaku, K., Kaneto, H., Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice. Biochem. Biophys. Res. Commun. 470:3 (2016), 772–782, 10.1016/j.bbrc.2015.10.109 (PubMed PMID: 26505796).
40. [40] Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., Honda, K., Suzuki, Y., Kawabe, Y., Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br. J. Pharmacol. 170:3 (2013), 519–531, 10.1111/bph.12269 (PubMed PMID: 23751087; PubMed Central PMCID: PMC3791991).
41. [41] Takahara, M., Shiraiwa, T., Matsuoka, T.A., Katakami, N., Shimomura, I., Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr. J. 62:1 (2015), 77–86, 10.1507/endocrj.EJ14-0335 (PubMed PMID: 25328035).
42. [42] Polidori, D., Mari, A., Ferrannini, E., Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57:5 (2014), 891–901, 10.1007/s00125-014-3196-x (PubMed PMID: 24585202; PubMed Central PMCID: PMC3980039).
43. [43] Thrailkill, K.M., Siddhanti, S.R., Fowlkes, J.L., Quarles, L.D., Differentiation of MC3T3-E1 osteoblasts is associated with temporal changes in the expression of IGF-I and IGFBPs. Bone 17:3 (1995), 307–313 (PubMed PMID: 8541146).
44. [44] Girasole, G., Passeri, G., Jilka, R.L., Manolagas, S.C., Interleukin-11: A new cytokine critical for osteoclast development. J. Clin. Invest. 93:4 (1994), 1516–1524, 10.1172/JCI117130 (PubMed PMID: 8163655; PubMed Central PMCID: PMC294166).
45. [45] Kim, H.N., Han, L., Iyer, S., de Cabo, R., Zhao, H., O'Brien, C.A., Manolagas, S.C., Almeida, M., Sirtuin1 suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol. Endocrinol. 29:10 (2015), 1498–1509, 10.1210/me.2015-1133 (PubMed PMID: 26287518; PubMed Central PMCID: PMC4588729).
46. [46] Fowlkes, J.L., Bunn, R.C., Liu, L., Wahl, E.C., Coleman, H.N., Cockrell, G.E., Perrien, D.S., Lumpkin, C.K. Jr., Thrailkill, K.M., Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 149:4 (2008), 1697–1704, 10.1210/en.2007-1408 (PubMed PMID: 18162513; PubMed Central PMCID: PMC2276714).